Suzhou Highfine Biotech Co., Ltd. (SHE:301393)

Suzhou Highfine Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Cash & Equivalents	202.45	408.66	361.08	1,740	99.32	78.05
Trading Asset Securities	831.08	902.02	1,346	30.76	60	45
Cash & Short-Term Investments	1,034	1,311	1,707	1,770	159.32	123.05
Cash Growth	-30.80%	-23.23%	-3.56%	1011.12%	29.48%	20.56%
Accounts Receivable	264.8	189.26	98.34	63.56	53.42	69.11
Other Receivables	1.62	1.44	11.78	0.49	1.71	3.47
Receivables	266.41	190.7	110.12	64.05	55.12	72.58
Inventory	188.16	161.18	116.7	115	113.45	78.89
Prepaid Expenses	-	-	0.03	-	-	-
Other Current Assets	83.2	27.43	10.1	14.69	24.77	15.72
Total Current Assets	1,571	1,690	1,944	1,964	352.67	290.24
Property, Plant & Equipment	899.01	631.42	320.39	286.46	206.24	142.63
Long-Term Investments	124.53	122.6	-	-	-	-
Goodwill	57.85	57.85	-	-	-	-
Other Intangible Assets	105.28	105.43	66.33	24.02	24.59	25.17
Long-Term Deferred Tax Assets	12.23	11.99	4.39	3.66	3.95	2.37
Long-Term Deferred Charges	1.13	0.35	0.1	0.08	0.26	0.29
Other Long-Term Assets	29	34.76	14.14	8.71	12.34	4.4
Total Assets	2,800	2,654	2,350	2,287	600.05	465.09

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Accounts Payable	154.4	77.65	27.21	24.9	36.46	25.59
Accrued Expenses	17.52	25.74	17.95	16.68	23.26	15.24
Short-Term Debt	-	10.01	-	-	-	-
Current Portion of Long-Term Debt	1.19	0.03	-	-	-	-
Current Portion of Leases	-	1.38	1.68	0.83	1.04	1.03
Current Income Taxes Payable	10.39	4.42	4.59	3.28	13.94	5.84
Current Unearned Revenue	3.27	0.78	1.38	0.61	0.6	2.34
Other Current Liabilities	34.28	118.86	18.35	19.53	34.04	34.8
Total Current Liabilities	221.06	238.87	71.16	65.84	109.33	84.84
Long-Term Debt	118.02	39.47	-	-	-	-
Long-Term Leases	-	0.44	1.6	0.72	0.39	1.17
Long-Term Unearned Revenue	8.18	9.22	7.65	8.45	7.94	6.52
Long-Term Deferred Tax Liabilities	6.88	7.24	0.94	0.07	0.12	-
Total Liabilities	354.15	295.24	81.35	75.08	117.77	92.53

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Common Stock	108	108	108	108	81	81
Additional Paid-In Capital	1,697	1,690	1,686	1,683	54.79	54.79
Retained Earnings	662.38	583.39	511.55	417.69	345.72	236.6
Treasury Stock	-33.42	-33.42	-42	-	-	-
Comprehensive Income & Other	7.36	4.95	4.44	2.99	0.77	0.18
Total Common Equity	2,441	2,353	2,268	2,212	482.28	372.57
Minority Interest	5.04	6.33	-	-	-	-
Shareholders' Equity	2,446	2,359	2,268	2,212	482.28	372.57
Total Liabilities & Equity	2,800	2,654	2,350	2,287	600.05	465.09

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Total Debt	119.22	51.33	3.28	1.56	1.43	2.2
Net Cash (Debt)	914.31	1,259	1,704	1,769	157.9	120.85
Net Cash Growth	-38.27%	-26.10%	-3.66%	1020.18%	30.65%	19.58%
Net Cash Per Share	8.52	11.75	15.75	19.12	1.95	1.50
Filing Date Shares Outstanding	107.18	107.18	106.97	108	81	81
Total Common Shares Outstanding	107.18	107.18	106.97	108	81	81
Working Capital	1,350	1,451	1,873	1,898	243.34	205.4
Book Value Per Share	22.78	21.95	21.20	20.48	5.95	4.60
Tangible Book Value	2,278	2,190	2,202	2,188	457.68	347.4
Tangible Book Value Per Share	21.25	20.43	20.58	20.26	5.65	4.29
Buildings	-	266.28	183.65	171.81	74.32	64.69
Machinery	-	320.25	163.79	76.02	65.92	61.8
Construction In Progress	-	217.39	21.65	72.45	87.92	28.48

Data Source: S&P Global Market Intelligence Last updated: Oct 23, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 10, 2026

Data Sources Report a data error